Key insights
- H.C. Wainwright downgraded Summit Therapeutics to Neutral from Buy due to competitive pressure from Merck's sacituzumab tirumotecan data, which showed a more favorable overall survival hazard ratio. This competitive threat could negatively impact Summit's ivonescimab, especially in certain patient subgroups. While other analysts maintain Buy ratings, this downgrade signals potential headwinds for Summit Therapeutics, influencing investor sentiment in the biotechnology sector.
Investing.com - H.C. Wainwright downgraded Summit Therapeutics plc (NASDAQ:SMMT) to Neutral from Buy on Thursday, citing competitive pressure from Merck & Co.’s sacituzumab tirumotecan data.
The firm removed its price target on Summit Therapeutics. H.C. Wainwright said sacituzumab tirumotecan combined with pembrolizumab showed an immature overall survival hazard ratio of 0.55, which could pressure Summit’s ivonescimab if the trend holds with longer follow-up.
The firm noted non-squamous progression-free survival appeared markedly better for Merck, while squamous results appeared similar. PD-L1 low patients showed markedly better results for Merck, while PD-L1 high patients appeared similar.
H.C. Wainwright said Summit has not provided a more mature overall survival update from its HARMONi-2 trial. The trial previously reported an immature overall survival hazard ratio of 0.777 at approximately 39% maturity that was favorable but not statistically significant.
The firm said it expected an update by year-end 2025 or early 2026. Summit Therapeutics has a PDUFA date of November 14, 2026.
In other recent news, Summit Therapeutics has been the focus of several analyst evaluations. Stifel reiterated its Buy rating with a price target of $45.00, emphasizing the potential of Ivonescimab in a significant drug class. UBS also maintained a Buy rating and set a $33.00 price target, projecting favorable outcomes for the HARMONi-6 trial readout expected in mid-2026. Meanwhile, H.C. Wainwright adjusted its price target from $30 to $23 but kept a Buy rating, noting no safety concerns from the HARMONi-3 trial.
In contrast, Bernstein downgraded Summit Therapeutics to an Underperform rating with a $7.70 price target, advising caution due to trial concerns. The independent Data Monitoring Committee recommended the continuation of the HARMONi-3 trial as planned, with no changes to the final analysis timeline. Stifel also initiated coverage with a Buy rating, underscoring the strategic positioning of Ivonescimab. These developments highlight varying analyst perspectives on Summit Therapeutics’ trial progress and strategic positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates SMMT alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if SMMT is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?